GSK plc

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

UK advanced medicine manufacturing capability received a boost last week with a trio of investments.

I’m really disappointed that a positive COVID test and self isolation period means I will miss both bioProcessUK conference and the official opening of AstraZeneca’s R&D HQ in Cambridge this week - two events I was really looking forward to. I do plan to participate in the UK Government's Life Science Council as it is a virtual meeting this time around.

My name is Ricky Casey and I am an Investigator within Biopharm Process Research at GSK in Stevenage. Following on from Roger McGilvray’s blog in June which detailed the overall aims of the BIA MAC LeaP program, I wanted to provide some insight into the follow-on instalment of our cohort’s two year journey together as it was my turn to host the group in July.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at J.P. Morgan Healthcare Week. 

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

J.P. Morgan Healthcare Conference 2025: Genomics announces Dr. Jose-Carlos Gutiérrez-Ramos as new board member to accelerate global expansion and life sciences R&D growth.

GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers.

Pension reform unlocks cash for UK life sciences, London Life Sciences Week and #bioProcessUK are here.

Relation Therapeutics announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

FUJIFILM Corporation is investing $83m to expand microbial production capacity of FUJIFILM Diosynth Biotechnologies in the UK. This will triple the plant’s current capacity of microbial production and it is fantastic to see an established international player like FUJIFILM making such a significant investment in its manufacturing capability in this country.